Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Blood (2015) 126 (23): 5322.

https://doi.org/10.1182/blood.V126.23.5322.5322

Published: 2015

Journal Articles

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Cara A. Rosenbaum, MD, Vishal Kukreti, MD, Jeffrey Zonder, MD, Daniel Lebovic, MD, Todd Zimmerman, MD, Jesus G. Berdeja, MD, Kathryn McDonnell, BS, Jessica Waite-Marin, MS, PA-C, Kent A. Griffith, Andrzej Jakubowiak, MD PhD

Blood (2014) 124 (21): 2109.

https://doi.org/10.1182/blood.V124.21.2109.2109

Published: 2014

Journal Articles

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD PhD, Enrique M Ocio, Sheeba K. Thomas, MD, Andreas Günther, MD, Yeow-Tee Goh, MBBS,MMed, Daniel Lebovic, MD, Andrzej Jakubowiak, MD PhD, Dongweon Song, F Xiang, Apurva Patel, K. Gary Vanasse, MD, Shaji Kumar, MD

Blood (2014) 124 (21): 301.

https://doi.org/10.1182/blood.V124.21.301.301

Published: 2014

Journal Articles

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Ravi Vij, MBBS, MD, Carol Ann Huff, MD, William I. Bensinger, MD, David S. Siegel, MD PhD, Sundar Jagannath, MD, Jesus Berdeja, MD, Nikoletta Lendvai, MD PhD, Daniel Lebovic, MD, Larry D. Anderson, MD PhD, Caitlin L. Costello, MD, Keith E. Stockerl-Goldstein, MD, Jacob P. Laubach, MD, Laurence Elias, MD, Fong Clow, ScD, Maria Fardis, PhD MBA, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Paul G. Richardson

Blood (2014) 124 (21): 31.

https://doi.org/10.1182/blood.V124.21.31.31

Published: 2014

Journal Articles

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Jagoda Jasielec, MD, Dominik Dytfeld, MD, PhD, Kent A. Griffith, MPH, MS, Kathryn McDonnell, BS, Daniel Lebovic, MD, Malathi Kandarpa, PhD, David H. Vesole, MD, PhD, Sundar Jagannath, MD, Melissa A. Mietzel, MS CCRP, Ravi Vij, MD, Malek Faham, MD, PhD, Liana Lee, BS, Erik H. van Beers, PhD, Martin H. van Vliet, PhD, Joan Levy, PhD, Mattina Alonge, MS, Shaun Rosebeck, PhD, Mark S. Kaminski, MD, Andrzej J. Jakubowiak, MD, PhD

Blood (2013) 122 (21): 3220.

https://doi.org/10.1182/blood.V122.21.3220.3220

Published: 2013

Journal Articles

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Marc S Raab, MD, Enrique M. Ocio, Sheeba K. Thomas, M.D., Andreas Günther, Daniel Lebovic, MD, Shaji K Kumar, MD, Andrzej J. Jakubowiak, MD, PhD, Dongweon Song, Fang Xiang, David Hynds, K. Gary Vanasse, M.D., Yeow Tee Goh, MD

Blood (2013) 122 (21): 3186.

https://doi.org/10.1182/blood.V122.21.3186.3186

Published: 2013

Journal Articles

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

Ranjana Advani, MD, Andy I. Chen, MD, PhD, Daniel Lebovic, MD, Mark W. Brunvand, MD, Andre Goy, MD, Julie E. Chang, MD, Ephraim Hochberg, Sreeni Yalamanchili, BSPharm, Robert Kahn, Dan Lu, Akiko Chai, MS, Yu-Waye Chu, Bruce D. Cheson, M.D.

Blood (2013) 122 (21): 4399.

https://doi.org/10.1182/blood.V122.21.4399.4399

Published: 2013

Journal Articles

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Erik H van Beers, PhD, Martin H. Van Vliet, PhD, Kenneth C. Anderson, MD, Ajai Chari, MD, Sundar Jagannath, MD, Andrzej Jakubowiak, MD, PhD, Shaji K Kumar, MD, Daniel Lebovic, MD, Joan Levy, PhD, Sagar Lonial, M.D., Donna E Reece, MD, FRCPC, Paul G. Richardson, MD, David S Siegel, MD, PhD, Keith Stewart, MBA, MB, CHB, Suzanne Trudel, MD, MSC, FRCPC, Ravi Vij, MD, Todd M. Zimmerman, MD, Rafael Fonseca, M.D.

Blood (2013) 122 (21): 1854.

https://doi.org/10.1182/blood.V122.21.1854.1854

Published: 2013

Journal Articles

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Paul G. Richardson, MD, Craig C Hofmeister, MD, Cara A Rosenbaum, MD, Myo Htut, MD, David H. Vesole, MD, PhD, Jesus Berdeja, MD, Michaela Liedtke, MD, Ajai Chari, MD, Stephen D Smith, MD, Daniel Lebovic, MD, Deborah Berg, RN, MSN, Eileen Liao, Ph.D, Neeraj Gupta, Ph.D, Alessandra Di Bacco, Ph.D, Jose Estevam, BS, MS, Ai-Min Hui, Rachid Baz, MD

Blood (2013) 122 (21): 535.

https://doi.org/10.1182/blood.V122.21.535.535

Published: 2013

Journal Articles

Recurrent STAT6 Mutations In Follicular Lymphoma

Sami Malek, MD, Mark S. Kaminski, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, PA-C, Kathryn Jacobi, NP, Kamlai Saiya-Cork, Dale Bixby, MD, PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mehmet Yildiz, MD

Blood (2013) 122 (21): 503.

https://doi.org/10.1182/blood.V122.21.503.503

Published: 2013

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 1636.

https://doi.org/10.1182/blood.V120.21.1636.1636

Published: 2012

Journal Articles

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Daniel Lebovic, MD, Mark S. Kaminski, MD, Tara B. Anderson, Kristen Detweiler-Short, Kent A. Griffith, Terri L. Jobkar, BSN, Malathi Kandarpa, PhD, Andrzej Jakubowiak, MD, PhD

Blood (2012) 120 (21): 1854.

https://doi.org/10.1182/blood.V120.21.1854.1854

Published: 2012

Journal Articles

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

Sami Malek, MD, Yifeng Li, MD, Hongxiu Li, PhD, Peter Ouillette, Sian Jones, PhD, Heather Fox, Kathryn Jacobi, Kamlai saiya-Cork, Dale Bixby, MD PhD, Daniel Lebovic, MD, Kerby Shedden, PhD, Michael Sabel, MD, Lawrence Marentette, MD, Vincent Cimmino, MD, Alfred Chang, MD, Mark S. Kaminski, MD

Blood (2012) 120 (21): 147.

https://doi.org/10.1182/blood.V120.21.147.147

Published: 2012

Journal Articles

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

Suzanne Trudel, MD, P. Leif Bergsagel, MD, Seema Singhal, M.D., Ruben Niesvizky, MD, Raymond L. Comenzo, MD, William I. Bensinger, MD, Daniel Lebovic, MD, YounJeong Choi, Dan Lu, Dorothy French, Elicia Penuel, William Ho, MD, PhD, Keith Stewart, MBA, MB, CHB

Blood (2012) 120 (21): 4029.

https://doi.org/10.1182/blood.V120.21.4029.4029

Published: 2012

Journal Articles

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Ranjana Advani, MD, Daniel Lebovic, MD, Mark Brunvand, MD, Andy I. Chen, MD, PhD, Andre Goy, MD, Julie E. Chang, MD, Lauren S Maeda, MD, William Ho, MD, PhD, Robert Kahn, Dan Lu, Zheng Su, Yu-Waye Chu, Bruce D. Cheson, MD

Blood (2012) 120 (21): 59.

https://doi.org/10.1182/blood.V120.21.59.59

Published: 2012

Journal Articles

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

Blood (2011) 118 (21): 631.

https://doi.org/10.1182/blood.V118.21.631.631

Published: 2011

Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD

Blood (2011) 118 (21): 3712.

https://doi.org/10.1182/blood.V118.21.3712.3712

Published: 2011

Journal Articles

Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial

Andrzej J Jakubowiak, MD, PhD, Dominik Dytfeld, MD, PhD, Sundar Jagannath, MD, David H. Vesole, MD, PhD, Tara B. Anderson, Brian K. Nordgren, Daniel Lebovic, MD, Keith E. Stockerl-Goldstein, MD, Kent A. Griffith, Melissa A. Hill, Colleen K. Harvey, Akari M. Dollard, Robert Ott, Susan L. Kelley, MD, Jennifer Barrickman, Michael Kauffman, MD, PhD, Ravi Vij, MD

Blood (2010) 116 (21): 862.

https://doi.org/10.1182/blood.V116.21.862.862

Published: 2010

Journal Articles

Serum Free Light Chain Analysis Improves Monitoring of Multiple Myeloma Patients Receiving First-Line Therapy with the Combination of Velcade, Doxil, and Dexamethasone (VDD).

Daniel Lebovic, MD, Tara Kendall, PA-C, Christine Brozo, PA-C, Amanda McAllister, BS, Malathi Hari, PhD, Sairah Alvi, PhD, Ewan J.D. Robson, PhD, Andrzej J. Jakubowiak, MD, PhD

Blood (2007) 110 (11): 2736.

https://doi.org/10.1182/blood.V110.11.2736.2736

Published: 2007

Journal Articles

Predictors of Survival in De Novo Cardiac Amyloidosis.

Raymond L. Comenzo, MD, Mathew Maurer, MD, Adam Cohen, MD, Hani Hassoun, MD, Ping Zhou, PhD, Ping Lu, PhD, Martin Fleisher, PhD, Daniel Lebovic, MD, Julie Feldstein, MD, Richard Steingart, MD, Stephen D. Nimer, MD

Blood (2007) 110 (11): 2870.

https://doi.org/10.1182/blood.V110.11.2870.2870

Published: 2007

NARROW

Low-Risk Multiple Myeloma By SKY92+ISS Validated in the Multiple Myeloma Genomics Initiative Study

Phase 1b/2 Study of Carfilzomib, Pomalidomide, and Dexamethasone (KPd) in Patients (Pts) with Lenalidomide-Exposed and/or -Refractory but Proteasome Inhibitor (PI)-Naive or -Sensitive Multiple Myeloma: A Multiple Myeloma Research Consortium Multi-Center Study

Phase 1 Study Update of the Novel Pan-Pim Kinase Inhibitor LGH447 in Patients with Relapsed/ Refractory Multiple Myeloma

Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Preliminary Phase 2 Results

Predictors Of Treatment Outcome With The Combination Of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) In Newly Diagnosed Multiple Myeloma (NDMM)

Phase 1 Study Of The Novel Pan-Pim Kinase Inhibitor LGH447 In Patients With Relapsed/ Refractory Multiple Myeloma

Final Results Of a Phase I Study Of The Anti-CD22 Antibody-Drug Conjugate (ADC) DCDT2980S With Or Without Rituximab (RTX) In Patients (Pts) With Relapsed Or Refractory (R/R) B-Cell Non-Hodgkin’s Lymphoma (NHL)

High Risk Multiple Myeloma Cases Are Identified In An MMRC Led Study By The SKY92 Gene Signature (MMprofiler)

Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data

Recurrent STAT6 Mutations In Follicular Lymphoma

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

A Phase II Study of Consolidation Treatment with Iodione-131 Tositumomab (Bexxar™) in Multiple Myeloma (MM)

Analysis of the Coding Genome of Follicular Lymphoma Identifies Multiple Novel Recurrently Mutated Genes

A Phase I Study of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S, a Fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

A Phase I Study of DCDT2980S, an Antibody-Drug Conjugate (ADC) Targeting CD22, in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Carfilzomib, Lenalidomide, and Dexamethasone In Newly Diagnosed Multiple Myeloma: Initial Results of Phase I/II MMRC Trial

Serum Free Light Chain Analysis Improves Monitoring of Multiple Myeloma Patients Receiving First-Line Therapy with the Combination of Velcade, Doxil, and Dexamethasone (VDD).

Predictors of Survival in De Novo Cardiac Amyloidosis.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only